低剂量吉西他滨联合奥沙利铂治疗浸润性尿路上皮癌的临床效果

Clinical efficacy of low dose gemcitabine combined with oxaliplatin in patients with invasive urothelial carcinoma

目的探索低剂量吉西他滨联合奥沙利铂治疗浸润性尿路上皮癌的临床效果。方法选择2012年1月至2012年12月间收治的76例浸润性尿路上皮癌患者,按治疗方式不同分为试验组和对照组,每组38例。试验组患者采用低剂量吉西他滨联合奥沙利铂治疗,对照组患者单用吉西他滨治疗,比较两组患者的临床有效率、不良反应和生存率。结果试验组和对照组患者的临床有效率分别为86.8%和57.9%,差异有统计学意义(P<0.05)。试验组和对照组患者的不良反应发生率分别为21.0%和44.8%,差异有统计学意义(P<0.05)。化疗后随访3个月至1年,试验组患者的生存率显著高于对照组,差异有统计学意义(P<0.05)。结论采用低剂量吉西他滨联合奥沙利铂治疗浸润性尿路上皮癌的临床效果确切,可有效延缓病情的进展,提高生存率,值得临床进一步推广。

Objective To investigate the efficacy of low dose of gemcitabine combined with oxali- platin in patients with invasive urothelial carcinoma. Methods 76 patients with invasive urothelial carcino- ma were collected and equally divided into observation group （38 cases） and control group （38 cases） ac- cording to different treatments from 2012 January to 2012 December. The observation group received low dose gemcitabine and oxaliplatin therapy, the control group only received gemcitabine therapy. The clinical efficacy, rate of adverse reactions and survival of both groups were compared after treatment. Results The clinical effective rates of observation group and control group were 86. 8% and 57.9% , respectively. The rate of adverse reactions of observation group （ 21.0% ） was significantly lower than that of control group （44. 8%, P 〈 O. 05 ）. Survival rate of observation group was significantly higher than that of control group after 3 month- and 1 year- follow-up. Conclusion Low dose of gemcitabine combined with oxaliplatin in the treatment of invasive urothelial carcinoma is effective, safe and high survival rate. It is worthy of clinical promotion.